145 related articles for article (PubMed ID: 21811251)
1. Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Shaw PH; Maughan TS; Clarke AR
Br J Cancer; 2011 Aug; 105(5):649-57. PubMed ID: 21811251
[TBL] [Abstract][Full Text] [Related]
2. Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Jameson MJ; Taniguchi LE; VanKoevering KK; Stuart MM; Francom CR; Mendez RE; Beckler AD; Carlson HT; Thomas CY; Khalil AA
J Oral Pathol Med; 2013 Apr; 42(4):332-8. PubMed ID: 23106397
[TBL] [Abstract][Full Text] [Related]
3. Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Alferez DG; Ryan AJ; Goodlad RA; Wright NA; Wilkinson RW
Int J Oncol; 2010 Oct; 37(4):767-72. PubMed ID: 20811697
[TBL] [Abstract][Full Text] [Related]
4. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice.
Alferez D; Wilkinson RW; Watkins J; Poulsom R; Mandir N; Wedge SR; Pyrah IT; Smith NR; Jackson L; Ryan AJ; Goodlad RA
Mol Cancer Ther; 2008 Mar; 7(3):590-8. PubMed ID: 18347145
[TBL] [Abstract][Full Text] [Related]
6. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Guix M; Faber AC; Wang SE; Olivares MG; Song Y; Qu S; Rinehart C; Seidel B; Yee D; Arteaga CL; Engelman JA
J Clin Invest; 2008 Jul; 118(7):2609-19. PubMed ID: 18568074
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
12. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
14. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
15. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Ninomiya T; Takigawa N; Ichihara E; Ochi N; Murakami T; Honda Y; Kubo T; Minami D; Kudo K; Tanimoto M; Kiura K
Mol Cancer Ther; 2013 May; 12(5):589-97. PubMed ID: 23443806
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
Keith RL; Karoor V; Mozer AB; Hudish TM; Le M; Miller YE
Lung Cancer; 2010 Oct; 70(1):37-42. PubMed ID: 20116128
[TBL] [Abstract][Full Text] [Related]
17. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.
Nautiyal J; Banerjee S; Kanwar SS; Yu Y; Patel BB; Sarkar FH; Majumdar AP
Int J Cancer; 2011 Feb; 128(4):951-61. PubMed ID: 20473900
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
[TBL] [Abstract][Full Text] [Related]
19. A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans.
Bongers G; Muniz LR; Pacer ME; Iuga AC; Thirunarayanan N; Slinger E; Smit MJ; Reddy EP; Mayer L; Furtado GC; Harpaz N; Lira SA
Gastroenterology; 2012 Sep; 143(3):730-740. PubMed ID: 22643351
[TBL] [Abstract][Full Text] [Related]
20. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
